Tevimbra® (tislelizumab-jsgr) – New indication
December 27, 2024 - BeiGene announced the FDA approval of Tevimbra (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) whose tumors express PD-L1 (≥ 1).
Top